SCHEMBL723758

SCHEMBL723758

Cn1cc(-c2ccc(-c3cc4nccc(-c5cccnc5)c4o3)cc2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 4/20 0.47
CCNC P24863 3/20 0.43
CDK8 P49336 3/20 0.43
CLK2 P49760 1/20 0.41
CLK3 P49761 1/20 0.41
FLT3 P36888 1/20 0.41
NEK2 P51955 1/20 0.41
ALK Q9UM73 1/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
MAP3K7 O43318 2/20 0.39
TAB1 Q15750 2/20 0.39
MCL1 Q07820 1/20 0.39
KDR P35968 2/20 0.38
AURKB Q96GD4 3/20 0.38
WNT1 P04628 2/20 0.38
GSK3B P49841 2/20 0.38
AURKA O14965 2/20 0.38
INCENP Q9NQS7 2/20 0.38
TPX2 Q9ULW0 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722505 0.89 CCNC (0.42) DYRK1ACCNCCDK8ALKMKNK1
SCHEMBL15209645 0.86 CCNC (0.39) CCNCCDK8ALKMKNK1MKNK2
SCHEMBL723361 0.85 MET (0.42) PIK3CACYP2C9
SCHEMBL723385 0.85 MTOR (0.43) CCNCCDK8ALKMKNK1MKNK2
SCHEMBL10268949 0.84 AURKB (0.46) CCNCCDK8ALKMAP3K7TAB1
SCHEMBL15209552 0.83 FGFR1 (0.41) CCNCCDK8PIK3CA
SCHEMBL721690 0.83 AURKB (0.38) CCNCCDK8ALKAURKBAURKA
SCHEMBL15216719 0.83 CCNC (0.41) CCNCCDK8FLT3ALKMKNK1
SCHEMBL722999 0.82 CCNC (0.43) CCNCCDK8ALKCCNA2CDK2
SCHEMBL725211 0.82 CCNC (0.40) CCNCCDK8FLT3MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB DYRK1A 738/4885CCNC 2402/4885CDK8 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.